Advertisement


Hielke-Martijn de Vries, MD, on Penile Cancer: New Data on Atezolizumab and Radiotherapy

2022 ASCO Genitourinary Cancers Symposium

Advertisement

Hielke-Martijn de Vries, MD, of the Netherlands Cancer Institute, discusses phase II findings on the use of atezolizumab with or without radiotherapy for patients with advanced squamous cell carcinoma of the penis. The study was designed to address the poor prognosis for this disease by exploring whether a protracted schedule of radiotherapy for locoregional disease, in combination with immunotherapy, could improve outcomes (Abstract 3).



Related Videos

Bladder Cancer

Wesley Yip, MD, on Urothelial Carcinoma: New Data on Neoadjuvant Gemcitabine and Cisplatin

Wesley Yip, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II results on neoadjuvant gemcitabine and cisplatin for high-grade upper tract urothelial carcinoma, which was well tolerated and demonstrated a favorable pathologic response rate. Dr. Yip notes that this treatment, given prior to nephroureterectomy, did not significantly delay surgery or increase perioperative complication rates.

Prostate Cancer

Xin Gao, MD, on Prostate Cancer: Early-Phase Results on Bavdegalutamide

Xin Gao, MD, of Massachusetts General Hospital, discusses phase I/II findings on bavdegalutamide, an androgen receptor protein degrader, which showed clinical activity in heavily pretreated patients with metastatic castration-resistant prostate cancer who received one to two prior novel hormonal agents.

Prostate Cancer
Immunotherapy

Tanya B. Dorff, MD, on Prostate Cancer: Early Data on PSCA-Targeted CAR T-Cell Therapy

Tanya B. Dorff, MD, of City of Hope National Medical Center, discusses the first-in-human phase I findings showing that prostate stem cell antigen (PSCA) CAR T-cell therapy is feasible in patients with metastatic castration-resistant prostate cancer, with preliminary antitumor activity exhibited.

Prostate Cancer

Fred Saad, MD, on Prostate Cancer: Results From the PROpel Trial on Olaparib and Abiraterone

Fred Saad, MD, of the University of Montreal Health Centre, discusses phase III findings demonstrating for the first time the clinical benefits of olaparib plus abiraterone in patients with metastatic castration-resistant prostate cancer, irrespective of their homologous recombination repair mutation status. This regimen led to significantly longer radiographic progression-free survival than placebo plus abiraterone (Abstract 11).

Prostate Cancer

Axel S. Merseburger, MD, on Prostate Cancer: New Data From the PRESIDE Trial on Enzalutamide, Docetaxel, and Prednisolone

Axel S. Merseburger, MD, of the University Hospital Schleswig-Holstein, discusses results from a phase IIIb study of chemotherapy-naive patients with metastatic castration-resistant prostate cancer who have been treated with docetaxel plus prednisolone and experienced disease progression on enzalutamide. The data suggest that continued enzalutamide plus docetaxel improved progression-free survival compared with placebo plus docetaxel (Abstract 15).

Advertisement

Advertisement



Advertisement